期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

双特异性抗体药物的研究进展 被引量：5

Progress in research of bispecific antibody drugs
原文传递
导出
摘要 双特异性抗体是一类具有双功能的抗体分子,可以同时特异性结合2个不同的抗原。由于其特异性和双功能性,现已成为抗体工程领域的研究热点,在肿瘤免疫治疗及自身免疫病等领域中具有广阔的应用前景。目前,至少有30多种双特异性抗体药物处于临床研究阶段。本文主要对双特异性抗体药物的开发历史、分子结构和设计策略、作用机制等进行简要综述。 Bispecific antibody is a kind of bi-functional protein composed of two different fragments and specifically binds to two different types of antigen. Due to its specificity and bi-function,bispecific antibody drugs have become a research focus in antibody engineering and have a wide application future in cancer immunotherapy and autoimmune disease. Nowadays,more than thirty kinds of bispecific antibody drugs are in clinical development. In this article we reviewed the recent progress in research of bispecific antibody drugs in development,design,and mechanism of action.
作者 郭婷婷 梁锦峰 聂磊 王海彬 白骅
机构地区 浙江海正药业股份有限公司 浙江省药品化妆品审评中心
出处 《中国新药杂志》 CAS CSCD 北大核心 2016年第5期518-523,共6页 Chinese Journal of New Drugs
基金 国家"重大新药创制"科技重大专项(2013ZX09402101-001)
关键词 双特异性抗体 双价抗体 双功能抗体 bispecific bispecific antibody bi-functional antibody
分类号 R979.5 [医药卫生—药品]
  • 相关文献

参考文献29

  • 1GARBER K. Bispecific antibodies rise again[ J]. Nat Rev Drug Discov,2014, 13(11) : 799 -801.
  • 2SPASEVSKA I. An outlook on bispecific antibodies: methods of production and therapeutic benefits [ M ]. France:Ens de Lyon, 2013, 1-7.
  • 3TOPP MS, KUFER P, GOKBUGET N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy- refractoryminimal residual disease in B-lineage acute lymphoblas- tic leukemia patients results in high response rate and prolonged leukemia-free survival [ J]. J Clini Oncol, 2011, 29 ( 18 ) : 2493 - 2498.
  • 4TOPP MS, GKBUGET N, STEIN AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B- precursor acute lymphoblastic leukaemia: a muhicentre, single- arm, phase2 study[J]. Lancet Oncol, 2015, 16(1):57-66.
  • 5KONTERMANN RE, BRINKMANN U- Bispecific antibodies [J]. Drug Discovery Today, 2015, 20(7): 838-847.
  • 6ZEIDLER R, REISBACH G, WOLLENBERG B, et al. Simulta- neous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing [J]. Jlmmunol, 1999, 163(3): 1246-1252.
  • 7HEISS MM, MURAWA P, KORALEWSKI P, et al. The trifune- tional antibody catumaxomab for the treatment of malignant ascites due to epithelial eancer: Results of a prospective randomized phase II/III trial[ J ]. Int J Cancer J Int Cancer, 2010, 127 (9) : 2209 - 2221.
  • 8BUHMANN R, MICHAEL S, JUERGEN H, et al. Immunother- apy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in re- lapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation : study protocol of an investigator-driven, open-la- bel, non-randomized, uncontrolled, dose-escalating Phase I/II- trial[J]. J Translat Med, 2013, 11:160.
  • 9RIDGWAY JB, PRESTA LG, CARTER P. ' Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodime- rization[J]. ProteinEng, 1996, 9(7): 617 -621.
  • 10CARTER P. Bispecific human IgG by design [ J]. J Immunol Met, 2001, 248(1 -2): 7-15.

二级参考文献12

  • 1Spasevska l. An outlook on bispecific antibodies: Methods of production and therapeutic benefits. Biosci Master Rev, 2014, 1-7.
  • 2Baeuerie PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res, 2009, 69(12):4941-4944.
  • 3Wu C, Ying H, Grinnell C, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol, 2007, 25(11):1290-1297.
  • 4Carter P. Bispecific human IgG by design. J Immunol Methods, 2001, 248(1-2):7-15.
  • 5Gramer MJ, van den Bremer ET, van Kampen MD, et al. Production of stable bispecific IgG I by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches. MAbs, 2013, 5(6):962-973.
  • 6Schaefer W, Regula JT, Bahner M, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA, 2011, 108(27):11187-11192.
  • 7Davis JH, Aperio C, Li Y, et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fe analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel, 2010, 23(4):195-202.
  • 8Bostrom J, Yu SF, Kan D, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science, 2009,323(5921):1610-1614.
  • 9Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs, 2009, 1(6):539-547.
  • 10Kristjansdottir K, Dizon D. HER-dimerization inhibitors: evaluating pertuzumab in women's cancers. Expert Opin Biol Ther, 2010, 10(2): 243-250.

共引文献1

同被引文献6

引证文献5

二级引证文献4

中国新药杂志
2016年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部